ImmunityBio (NASDAQ:IBRX – Get Free Report) and CERo Therapeutics (NASDAQ:CERO – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.
Analyst Ratings
This is a summary of recent recommendations for ImmunityBio and CERo Therapeutics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ImmunityBio | 0 | 1 | 0 | 1 | 3.00 |
CERo Therapeutics | 0 | 0 | 0 | 0 | N/A |
ImmunityBio currently has a consensus target price of $4.75, suggesting a potential downside of 12.68%. Given ImmunityBio’s higher possible upside, research analysts plainly believe ImmunityBio is more favorable than CERo Therapeutics.
Profitability
Net Margins | Return on Equity | Return on Assets | |
ImmunityBio | -45,691.66% | N/A | -108.04% |
CERo Therapeutics | N/A | N/A | -67.60% |
Risk and Volatility
ImmunityBio has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of -0.5, indicating that its share price is 150% less volatile than the S&P 500.
Earnings & Valuation
This table compares ImmunityBio and CERo Therapeutics”s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
ImmunityBio | $620,000.00 | 6,111.49 | -$583.20 million | ($0.97) | -5.61 |
CERo Therapeutics | N/A | N/A | -$2.54 million | N/A | N/A |
CERo Therapeutics has lower revenue, but higher earnings than ImmunityBio.
Insider and Institutional Ownership
8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 83.4% of ImmunityBio shares are held by insiders. Comparatively, 18.0% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
ImmunityBio beats CERo Therapeutics on 5 of the 9 factors compared between the two stocks.
About ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
About CERo Therapeutics
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.